Skip to main content
Erschienen in: Calcified Tissue International 1/2015

01.01.2015 | Original Research

Long-Term Treatment with Eldecalcitol (1α, 25-Dihydroxy-2β- (3-hydroxypropyloxy) Vitamin D3) Suppresses Bone Turnover and Leads to Prevention of Bone Loss and Bone Fragility in Ovariectomized Rats

verfasst von: Satoshi Takeda, Susan Y. Smith, Tatsuya Tamura, Hitoshi Saito, Fumiaki Takahashi, Rana Samadfam, Solomon Haile, Nancy Doyle, Koichi Endo

Erschienen in: Calcified Tissue International | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study is to estimate the efficacy of eldecalcitol (1α, 25-Dihydroxy-2β- (3-hydroxypropyloxy) vitamin D3; ELD) on bone metabolism after long-term administration. Six-month-old Wistar–Imamichi rats were ovariectomized (OVX) and administered ELD orally at doses of 7.5, 15, or 30 ng/kg daily. Bone mineral density (BMD), urinary excretion of deoxypyridinoline (DPD), a bone resorption marker, and serum total alkaline phosphatase (ALP), a surrogate marker of bone formation, were assessed after 3, 6, and 12 months of treatment. After 12 months of treatment, the biomechanical strength of the L4 lumbar vertebra and femoral shaft was measured, and bone histomorphometry was performed on the L3 lumbar vertebra and the tibia diaphysis. ELD prevented OVX-induced decreases in BMD of the lumbar vertebrae and femur throughout the treatment period. ELD significantly suppressed OVX-induced increases in urinary DPD excretion throughout the treatment period with minimal effects on ALP. OVX resulted in significant decreases in ultimate load and stiffness of the L4 lumbar vertebra and femoral shaft, and ELD significantly prevented the reduction in these biomechanical parameters. Bone histomorphometry at the L3 lumbar vertebra revealed that OVX induced increases in bone resorption parameters (osteoclast surface and osteoclast number) and bone formation parameters (osteoblast surface, osteoid surface, and bone formation rate), and ELD suppressed these parameters after 12 months treatment. Activation frequency, which was elevated in the OVX/vehicle group, was significantly suppressed to baseline levels in ELD-treated groups, indicating that ELD maintained bone turnover at a normal level. ELD also prevented OVX-induced deterioration of microstructure in trabecular and cortical bone. These results indicated that long-term treatment of OVX rats with ELD suppressed bone turnover, and prevented OVX-induced bone loss, deterioration of bone microstructure, and reduction in bone biomechanical strength.
Literatur
1.
Zurück zum Zitat Miyamoto K, Murayama E, Ochi K, Watanabe H, Kubodera N (1993) Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2 beta-position. Chem Pharm Bull (Tokyo) 41:1111–1113CrossRef Miyamoto K, Murayama E, Ochi K, Watanabe H, Kubodera N (1993) Synthetic studies of vitamin D analogues. XIV. Synthesis and calcium regulating activity of vitamin D3 analogues bearing a hydroxyalkoxy group at the 2 beta-position. Chem Pharm Bull (Tokyo) 41:1111–1113CrossRef
2.
Zurück zum Zitat Ono Y, Watanabe H, Shiraishi A, Takeda S, Higuchi Y, Sato K, Tsugawa N, Okano T, Kobayashi T, Kubodera N (1997) Synthetic studies of vitamin D analogs. XXIV. Synthesis of active vitamin D3 analogs substituted at the 2 beta-position and their preventive effects on bone mineral loss in ovariectomized rats. Chem Pharm Bull (Tokyo) 45:1626–1630CrossRef Ono Y, Watanabe H, Shiraishi A, Takeda S, Higuchi Y, Sato K, Tsugawa N, Okano T, Kobayashi T, Kubodera N (1997) Synthetic studies of vitamin D analogs. XXIV. Synthesis of active vitamin D3 analogs substituted at the 2 beta-position and their preventive effects on bone mineral loss in ovariectomized rats. Chem Pharm Bull (Tokyo) 45:1626–1630CrossRef
3.
Zurück zum Zitat Ono Y, Kawase A, Watanabe H, Shiraishi A, Takeda S, Higuchi Y, Sato K, Yamauchi T, Mikami T, Kato M, Tsugawa N, Okano T, Kubodera N (1998) Syntheses and preventive effects of analogues related to 1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (ED-71) on bone mineral loss in ovariectomized rats. Bioorg Med Chem 6:2517–2523CrossRefPubMed Ono Y, Kawase A, Watanabe H, Shiraishi A, Takeda S, Higuchi Y, Sato K, Yamauchi T, Mikami T, Kato M, Tsugawa N, Okano T, Kubodera N (1998) Syntheses and preventive effects of analogues related to 1α,25-dihydroxy-2β-(3-hydroxypropoxy)vitamin D3 (ED-71) on bone mineral loss in ovariectomized rats. Bioorg Med Chem 6:2517–2523CrossRefPubMed
4.
Zurück zum Zitat Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Takita Y, Nishii Y (1989) Regulatory activities of 2β-(3-hydroxypropoxy)-1α, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem Biophys Res Commun 163:1444–1449CrossRefPubMed Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Takita Y, Nishii Y (1989) Regulatory activities of 2β-(3-hydroxypropoxy)-1α, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem Biophys Res Commun 163:1444–1449CrossRefPubMed
5.
Zurück zum Zitat Hatakeyama S, Nagashima S, Imai N, Takahashi K, Ishihara J, Sugita A, Nihei T, Saito H, Takahashi F, Kubodera N (2007) Synthesis and biological evaluation of a 3-positon epimer of 1α,25-dihydroxy-2β-(3-hydroxypropoxy) vitamin D3 (ED-71). J Steroid Biochem Mol Biol 103:222–226CrossRefPubMed Hatakeyama S, Nagashima S, Imai N, Takahashi K, Ishihara J, Sugita A, Nihei T, Saito H, Takahashi F, Kubodera N (2007) Synthesis and biological evaluation of a 3-positon epimer of 1α,25-dihydroxy-2β-(3-hydroxypropoxy) vitamin D3 (ED-71). J Steroid Biochem Mol Biol 103:222–226CrossRefPubMed
6.
Zurück zum Zitat Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures—a randomized, active comparator, double-blind study. Bone 49:605–612CrossRefPubMed Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures—a randomized, active comparator, double-blind study. Bone 49:605–612CrossRefPubMed
7.
Zurück zum Zitat Matsumoto T, Takano T, Yamakido S, Takahashi F, Tsuji N (2010) Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol 121:261–264CrossRefPubMed Matsumoto T, Takano T, Yamakido S, Takahashi F, Tsuji N (2010) Comparison of the effects of eldecalcitol and alfacalcidol on bone and calcium metabolism. J Steroid Biochem Mol Biol 121:261–264CrossRefPubMed
8.
Zurück zum Zitat Uchiyama Y, Higuchi Y, Takeda S, Masaki T, Shira-ishi A, Sato K, Kubodera N, Ikeda K, Ogata E (2002) ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30:582–588CrossRefPubMed Uchiyama Y, Higuchi Y, Takeda S, Masaki T, Shira-ishi A, Sato K, Kubodera N, Ikeda K, Ogata E (2002) ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30:582–588CrossRefPubMed
9.
Zurück zum Zitat Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y (1996) Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res 11:325–336CrossRefPubMed Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y (1996) Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res 11:325–336CrossRefPubMed
10.
Zurück zum Zitat de Freitas PH, Hasegawa T, Takeda S, Sasaki M, Tabata C, Oda K, Li M, Saito H, Amizuka N (2011) Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 49:335–342CrossRefPubMed de Freitas PH, Hasegawa T, Takeda S, Sasaki M, Tabata C, Oda K, Li M, Saito H, Amizuka N (2011) Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 49:335–342CrossRefPubMed
11.
Zurück zum Zitat Saito H, Takeda S, Amizuka N (2013) Eldecalcitol and calcitriol stimulates ‘bone minimodeling’, focal bone formation without prior bone resorption, in rat trabecular bone. J Steroid Biochem Mol Biol 136:178–182CrossRefPubMed Saito H, Takeda S, Amizuka N (2013) Eldecalcitol and calcitriol stimulates ‘bone minimodeling’, focal bone formation without prior bone resorption, in rat trabecular bone. J Steroid Biochem Mol Biol 136:178–182CrossRefPubMed
12.
Zurück zum Zitat Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301CrossRefPubMed Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301CrossRefPubMed
13.
Zurück zum Zitat Schneider JP (2009) Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 64:18–23PubMed Schneider JP (2009) Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 64:18–23PubMed
14.
Zurück zum Zitat Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37–44CrossRefPubMed Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37–44CrossRefPubMed
15.
Zurück zum Zitat Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362CrossRefPubMed Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362CrossRefPubMed
16.
Zurück zum Zitat Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952CrossRefPubMed Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952CrossRefPubMed
17.
Zurück zum Zitat Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789CrossRefPubMed Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789CrossRefPubMed
18.
Zurück zum Zitat Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M (2003) New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008–2015CrossRefPubMed Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M (2003) New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008–2015CrossRefPubMed
19.
Zurück zum Zitat Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480CrossRefPubMedCentralPubMed Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD (2007) Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22:1502–1509CrossRefPubMed Chapurlat RD, Arlot M, Burt-Pichat B, Chavassieux P, Roux JP, Portero-Muzy N, Delmas PD (2007) Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22:1502–1509CrossRefPubMed
21.
Zurück zum Zitat Allen MR, Iwata K, Phipps R, Burr DB (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872–879CrossRefPubMed Allen MR, Iwata K, Phipps R, Burr DB (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872–879CrossRefPubMed
22.
Zurück zum Zitat Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512–520CrossRefPubMed Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512–520CrossRefPubMed
23.
Zurück zum Zitat Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531CrossRefPubMed Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531CrossRefPubMed
24.
Zurück zum Zitat Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:1759–1765CrossRefPubMed Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:1759–1765CrossRefPubMed
25.
Zurück zum Zitat Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H (2007) Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41:378–385CrossRefPubMed Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H (2007) Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41:378–385CrossRefPubMed
26.
Zurück zum Zitat Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14:595–608CrossRefPubMed Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14:595–608CrossRefPubMed
27.
Zurück zum Zitat Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610CrossRefPubMed Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610CrossRefPubMed
28.
Zurück zum Zitat Ito M, Nishida A, Koga A, Ikeda S, Shiraishi A, Uetani M, Hayashi K, Nakamura T (2002) Contribution of trabecular and cortical components to the mechanical properties of bone and their regulating parameters. Bone 31:351–358CrossRefPubMed Ito M, Nishida A, Koga A, Ikeda S, Shiraishi A, Uetani M, Hayashi K, Nakamura T (2002) Contribution of trabecular and cortical components to the mechanical properties of bone and their regulating parameters. Bone 31:351–358CrossRefPubMed
29.
Zurück zum Zitat Harada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda H, Udagawa N, Suda T, Takahashi N (2012) Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 27:461–473CrossRefPubMed Harada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda H, Udagawa N, Suda T, Takahashi N (2012) Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 27:461–473CrossRefPubMed
30.
Zurück zum Zitat Kikuta J, Kawamura S, Okiji F, Shirazaki M, Sakai S, Saito H, Ishii M (2013) Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci USA 110:7009–7013CrossRefPubMedCentralPubMed Kikuta J, Kawamura S, Okiji F, Shirazaki M, Sakai S, Saito H, Ishii M (2013) Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci USA 110:7009–7013CrossRefPubMedCentralPubMed
31.
Zurück zum Zitat Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K (2006) c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest 116:528–535CrossRefPubMedCentralPubMed Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K (2006) c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest 116:528–535CrossRefPubMedCentralPubMed
32.
Zurück zum Zitat Sakai S, Takaishi H, Matsuzaki K, Kaneko H, Furukawa M, Miyauchi Y, Shiraishi A, Saito K, Tanaka A, Taniguchi T, Suda T, Miyamoto T, Toyama Y (2009) 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab 27:643–652CrossRefPubMed Sakai S, Takaishi H, Matsuzaki K, Kaneko H, Furukawa M, Miyauchi Y, Shiraishi A, Saito K, Tanaka A, Taniguchi T, Suda T, Miyamoto T, Toyama Y (2009) 1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression. J Bone Miner Metab 27:643–652CrossRefPubMed
33.
Zurück zum Zitat Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y (1994) A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 54:142–149CrossRefPubMed Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y (1994) A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1 alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 54:142–149CrossRefPubMed
34.
Zurück zum Zitat Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 15:770–779CrossRefPubMed Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E (2000) Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 15:770–779CrossRefPubMed
35.
Zurück zum Zitat Li M, Healy DR, Simmons HA, Ke HZ, Thompson DD (2003) Alfacalcidol restores cancellous bone in ovariectomized rats. J Musculoskelet Neuronal Interact 3:39–46PubMed Li M, Healy DR, Simmons HA, Ke HZ, Thompson DD (2003) Alfacalcidol restores cancellous bone in ovariectomized rats. J Musculoskelet Neuronal Interact 3:39–46PubMed
36.
Zurück zum Zitat Liu XQ, Chen HY, Tian XY, Setterberg RB, Li M, Jee WS (2008) Alfacalcidol treatment increases bone mass from anticatabolic and anabolic effects on cancellous and cortical bone in intact female rats. J Bone Miner Metab 26:425–435CrossRefPubMed Liu XQ, Chen HY, Tian XY, Setterberg RB, Li M, Jee WS (2008) Alfacalcidol treatment increases bone mass from anticatabolic and anabolic effects on cancellous and cortical bone in intact female rats. J Bone Miner Metab 26:425–435CrossRefPubMed
37.
Zurück zum Zitat Colin EM, Van Den Bemd GJ, Van Aken M, Christakos S, De Jonge HR, Deluca HF, Prahl JM, Birkenhäger JC, Buurman CJ, Pols HA, Van Leeuwen JP (1999) Evidence for involvement of 17beta-estradiol in intestinal calcium absorption independent of 1,25-dihydroxyvitamin D3 level in the Rat. J Bone Miner Res 14:57–64CrossRefPubMed Colin EM, Van Den Bemd GJ, Van Aken M, Christakos S, De Jonge HR, Deluca HF, Prahl JM, Birkenhäger JC, Buurman CJ, Pols HA, Van Leeuwen JP (1999) Evidence for involvement of 17beta-estradiol in intestinal calcium absorption independent of 1,25-dihydroxyvitamin D3 level in the Rat. J Bone Miner Res 14:57–64CrossRefPubMed
38.
Zurück zum Zitat Dong XL, Zhang Y, Wong MS (2014) Estrogen deficiency-induced Ca balance impairment is associated with decrease in expression of epithelial Ca transport proteins in aged female rats. Life Sci 96:26–32CrossRefPubMed Dong XL, Zhang Y, Wong MS (2014) Estrogen deficiency-induced Ca balance impairment is associated with decrease in expression of epithelial Ca transport proteins in aged female rats. Life Sci 96:26–32CrossRefPubMed
39.
Zurück zum Zitat Liel Y, Shany S, Smirnoff P, Schwartz B (1999) Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 140:280–285PubMed Liel Y, Shany S, Smirnoff P, Schwartz B (1999) Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 140:280–285PubMed
40.
Zurück zum Zitat Brown AJ, Ritter CS (2011) The vitamin D analog 1α,25-Dihydroxy-2β-(3-Hydroxypropyloxy) vitamin D(3) (Eldecalcitol) is a potent regulator of calcium and phosphate metabolism. Calcif Tissue Int 89:372–378CrossRefPubMed Brown AJ, Ritter CS (2011) The vitamin D analog 1α,25-Dihydroxy-2β-(3-Hydroxypropyloxy) vitamin D(3) (Eldecalcitol) is a potent regulator of calcium and phosphate metabolism. Calcif Tissue Int 89:372–378CrossRefPubMed
Metadaten
Titel
Long-Term Treatment with Eldecalcitol (1α, 25-Dihydroxy-2β- (3-hydroxypropyloxy) Vitamin D3) Suppresses Bone Turnover and Leads to Prevention of Bone Loss and Bone Fragility in Ovariectomized Rats
verfasst von
Satoshi Takeda
Susan Y. Smith
Tatsuya Tamura
Hitoshi Saito
Fumiaki Takahashi
Rana Samadfam
Solomon Haile
Nancy Doyle
Koichi Endo
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 1/2015
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-014-9937-5

Weitere Artikel der Ausgabe 1/2015

Calcified Tissue International 1/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.